docetaxel anhydrous has been researched along with methotrexate in 96 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.13) | 18.2507 |
| 2000's | 47 (48.96) | 29.6817 |
| 2010's | 40 (41.67) | 24.3611 |
| 2020's | 6 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Akaza, H; Hattori, K | 1 |
| Ardiet, CJ; Bernard, E; Droz, JP; Guillot, A; Peguy, M; Rebattu, P; Tranchand, B; Zanetta, S | 1 |
| Bartholomeus, S; Crown, J; Di Leo, A; Dolci, S; Duffy, K; Larsimont, D; Nogaret, JM; O'Higgins, N; Paesmans, M; Piccart, MJ; Riva, A; Rowan, S | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, M; Malmström, P; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Pluzanska, A; Sjödin, M; Sjöström, J | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Boguslawski, KV; Heikkilä, P; Malmström, P; Mjaaland, I; Ostenstadt, B; Räisänen-Sokolowski, A; Saksela, E; Sjöström, J; Valvere, V; Wist, E | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA; Tsavaris, N | 1 |
| Tashiro, H | 1 |
| Bittner, C; Feyerabend, T; Peters, SO; Raap, M; Remmert, S; Robins, IH; Sieg, P; Sommer, K; Wiedemann, GJ | 1 |
| de Wit, R; Loos, WJ; Louwerens, M; Smorenburg, C; Sparreboom, A; Verweij, J | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Collan, J; Franssila, K; Malmström, P; Mjaaland, I; Saksela, E; Sjöström, J; Skiöld-Petterson, D; Valvere, V; von Boguslawski, K; Wist, E; Østenstad, B | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
| Culine, S | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Filipits, M; Jakesz, R; Pirker, R; Pohl, G; Rudas, M; Steger, GG; Stranzl, T; Taucher, S | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Motoyama, H; Tasaki, A | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Bamias, C; Deliveliotis, C; Dimopoulos, MA; Gika, D; Kalofonos, C; Kosmidis, P; Kourousis, C; Koutras, A; Mitropoulos, D; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Xiros, N; Zervas, A | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Blay, JY; Bleuze, JP; Bompas, E; Chaigneau, L; Cupissol, D; Guardiola, E; Madroszyk, A; Peyrade, F; Pivot, X; Ronchin, P; Schneider, M; Tchiknavorian, X | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T | 1 |
| Blomqvist, C; Larsson, R; Nygren, P; Villman, K | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Jida, M; Kubo, M; Maeda, H; Miyatani, K; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Yamane, M | 1 |
| Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N | 1 |
| Lorusso, V | 1 |
| Cheung, PS; Epstein, RJ; Leung, TW | 1 |
| Bandou, E; Endou, Y; Sasaki, T; Sawa, T; Sugarbaker, PH; Yonemura, Y; Yoshimitsu, Y | 1 |
| Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C | 1 |
| Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Christodoulou, C; Economopoulos, T; Efstratiou, I; Fountzilas, G; Gogas, H; Papadimitriou, C; Papakostas, P; Pectasides, D; Skarlos, D; Timotheadou, E | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
| Colozza, M; D'Aiuto, G; De Maio, E; de Matteis, A; De Placido, S; Di Rella, F; Gallo, C; Gori, S; Gravina, A; Labonia, V; Landi, G; Lauria, R; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, G; Thomas, R | 1 |
| Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Andersson, M; Azambuja, E; Balil, A; Crown, JP; Dolci, S; Francis, P; Gelber, RD; Gnant, M; Gutierrez, J; Láng, I; Nordenskjöld, B; Pestalozzi, BC; Piccart-Gebhart, M; Quinaux, E; Viale, G | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Castadot, P; Chargari, C; Di Leo, A; Magné, N; Philippson, C; Van Houtte, P | 1 |
| Haid, A; Konstantiniuk, P; Kugler, F; Pöstlberger, S; Reitsamer, R; Roka, S; Tausch, C | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Castellón, EA; Contreras, HR; Huidobro, C; McCubrey, JA; Mendoza, P; Sánchez, C; Vergara, J | 1 |
| Bernard, R; Braun, M; Harbeck, N; Ihbe-Heffinger, A; Jacobs, VR; Kuhn, W; Nitz, U; Sattler, D; Wagenpfeil, S | 1 |
| Teng, KY; Xu, RH | 1 |
| Budryk, M; Byrski, T; Dent, R; Gronwald, J; Grzybowska, E; Huzarski, T; Lubinski, J; Mierzwa, T; Narod, S; Siolek, M; Stawicka, M; Szwiec, M; Wisniowski, R | 1 |
| Alvarez, RH; Booser, DJ; Cristofanilli, M; Gonzalez-Angulo, AM; Guerra, L; Hortobagyi, GN; Kau, SW; Sahin, AA; Strom, EA; Valero, V | 1 |
| Barnadas, A | 1 |
| Cui, L; Huang, XE; Jiang, Y; Tang, JH; Xiang, J; Yan, PW | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Barrett-Lee, P; Bliss, J; Bloomfield, D; Cameron, D; Campbell, HE; Dunn, J; Earl, H; Ellis, P; Epstein, D; Gray, AM; Griffin, S; Harris, AL; Hiller, L; Hopwood, P; Johnson, L; Manca, A; Poole, C; Sculpher, MJ; Yarnold, J | 1 |
| Borsellino, N; Gebbia, V; Serretta, V; Valerio, MR | 1 |
| Hirama, M; Horiuchi, C; Ishitoya, J; Komatsu, M; Matsuda, H; Mori, M; Niho, T; Nishimura, G; Sakuma, Y; Shiono, O; Taguch, T; Takahashi, M; Tsukuda, M | 1 |
| Imholz, ALT; Laddach, N; Lips, EH; Mulder, L; Oonk, AMM; Rodenhuis, S; Savola, SP; Smits, MM; van Rijn, C; Wesseling, J | 1 |
| Han, HS; Jung, S; Kang, HS; Kim, SW; Lee, H; Lee, KS; Lee, S; Park, IH; Ro, J | 1 |
| Papachristopoulou, G; Scorilas, A; Talieri, M | 1 |
| Andersson, M; Buyse, M; Crown, J; De Azambuja, E; Dell'orto, P; Di Leo, A; Francis, PA; Gelber, RD; Gutiérrez, J; Harvey, V; Jakesz, R; Larsimont, D; Margeli Vila, M; Nordenskjöld, B; Oakman, C; Piccart-Gebhart, M; Punzalan, L; Quinaux, E; Steinberg, I; Thürlimann, B; Viale, G | 1 |
| Crown, JP; de Azambuja, E; Di Leo, A; Francis, P; Hitre, E; Loi, S; Michiels, S; Piccart, MJ; Piette, F; Quinaux, E; Rouas, G; Salgado, R; Sirtaine, N; Sotiriou, C; Van Eenoo, F; Viale, G | 1 |
| Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC | 1 |
| Ilson, DH | 1 |
| Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| A'hern, RP; Barrett-Lee, P; Bartlett, JM; Bliss, JM; Dowsett, M; Ellis, IO; Ellis, P; Gillett, C; Hanby, A; Irshad, S; Johnston, S; Pinder, SE; Tutt, A | 1 |
| Itoh, F; Maeda, I; Miyoshi, Y; Ohta, T; Oikawa, R; Tsuchiya, K; Tsugawa, K; Watanabe, Y; Wu, W | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Ding, C; Jia, L; Li, W; Li, Y; You, W; Zhai, B; Zhang, B; Zhi, H | 1 |
| Wang, W; Wang, Z; Xiao, X | 1 |
| Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Chen, K; Duan, WM; Gong, FR; Gui, Q; Li, DM; Li, W; Lian, L; Liu, L; Shen, M; Tao, M; Wang, WJ; Wu, MY; Xu, MD; Zhu, J | 1 |
| Golovin, YI; Klyachko, NL; Korenkov, VV; Kuznetsova, NR; Markvicheva, EA; Privalova, AM; Uglanova, SV; Vodovozova, EL | 1 |
| Cai, Y; Chen, M; Fang, X; He, C; Li, P; Wang, Y; Xiao, F | 1 |
| Adili, A; Esfehani, A; Jafarpour-Sadegh, F; Mesgari, M; Montazeri, V; Pirouzpanah, S; Rashidi, MR | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Ahn, MJ; Burtness, B; Cheng, J; Cohen, EEW; Dinis, J; Harrington, KJ; Le Tourneau, C; Licitra, L; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Zhang, P | 1 |
| Wollenberg, B | 1 |
| Ajona, D; Calvo, A; Cirauqui, C; de Aberasturi, AL; de Andrea, C; Exposito, F; Guruceaga, E; Montuenga, LM; Pio, R; Redin, E; Redrado, M; Vicent, S; Villalba, M | 1 |
| Cocks, K; Contente, M; DeRosa, M; Shaw, JW; Simpson, S; Taylor, FC | 1 |
| Christiansen, H; Hermann, RM | 1 |
| Abrams, J; Albain, KS; Badve, SS; Berenberg, JL; Brufsky, AM; Dees, EC; Desbiens, C; Ellis, MJ; Geyer, CE; Goetz, MP; Goggins, TF; Gomez, HL; Gray, RJ; Hayes, DF; Kaklamani, VG; Keane, MM; Lively, T; Mahalcioiu, C; Makower, DF; Mayer, IA; Olson, JA; Paik, S; Reddy, PS; Saphner, TJ; Sledge, GW; Sparano, JA; Toppmeyer, DL; Wagner, LI; Wood, WC | 1 |
| Ji, M; Wei, W; Wu, CP; Yang, X | 1 |
| Bins, S; Mathijssen, RHJ | 1 |
| Cohen, EEW; Harrington, KJ; Soulières, D; Swaby, RF | 1 |
| Biganzoli, E; Clatot, F; Crown, J; de Azambuja, E; De Bortoli, D; Demicheli, R; Desmedt, C; Di Leo, A; Fornili, M; Francis, PA; Piccart, M; Sotiriou, C; Viale, G | 1 |
| Abbaspour-Ravasjani, S; Haghbin Nazarpak, M; Hamishehkar, H; Mahoutforoush, A; Solouk, A | 1 |
| Banda, K; Gadi, VK; Indorf, A; Jung, L; Miske, A; Nelson, K | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
12 review(s) available for docetaxel anhydrous and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Meningeal Neoplasms; Methotrexate; Mitoxantrone; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Standard chemotherapy for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Practice Guidelines as Topic; Prognosis; Taxoids | 2000 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
What news in urological cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Palliative Care; Patient Selection; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2005 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cucurbitacins; Docetaxel; Drug Therapy, Combination; Humans; Methotrexate; Molecular Conformation; Neoplasm Invasiveness; Neoplasms; Phytotherapy; Signal Transduction; Structure-Activity Relationship; Taxoids | 2015 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
33 trial(s) available for docetaxel anhydrous and methotrexate
| Article | Year |
|---|---|
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Methotrexate; Paclitaxel; Reproducibility of Results; Solvents; Spectrophotometry, Ultraviolet; Taxoids | 1999 |
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2000 |
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Synergism; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2004 |
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2005 |
Preoperative second-line chemotherapy induces objective responses in primary breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Taxoids | 2006 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Italy; Methotrexate; Patient Compliance; Taxoids; Treatment Outcome | 2008 |
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Odds Ratio; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Failure | 2008 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Germany; Health Care Costs; Humans; Male; Methotrexate; Middle Aged; Prevalence; Taxoids; Treatment Outcome | 2009 |
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Taxoids | 2010 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Taxoids; Young Adult | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Treatment Outcome | 2013 |
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; tau Proteins; Taxoids | 2014 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2015 |
Effects of Fresh Yellow Onion Consumption on CEA, CA125 and Hepatic Enzymes in Breast Cancer Patients: A Double- Blind Randomized Controlled Clinical Trial.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; CA-125 Antigen; Carcinoembryonic Antigen; Cyclophosphamide; Diet; Docetaxel; Double-Blind Method; Doxorubicin; Feeding Behavior; Female; Fluorouracil; Humans; Liver; Membrane Proteins; Methotrexate; Middle Aged; Onions; Placebos; Plant Preparations; Taxoids | 2015 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck | 2019 |
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Follow-Up Studies; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Nivolumab; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Survival | 2019 |
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Young Adult | 2020 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
51 other study(ies) available for docetaxel anhydrous and methotrexate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Topics: Acetone; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical Precipitation; Chromatography, High Pressure Liquid; Docetaxel; Humans; Hydroxylation; Kinetics; Methanol; Methotrexate; Neoplasms; Paclitaxel; Rats; Rats, Wistar; Sensitivity and Specificity; Taxoids | 1999 |
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antigens, Nuclear; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Docetaxel; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Paraffin Embedding; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Randomized Controlled Trials as Topic; Taxoids; Tumor Suppressor Protein p53 | 2000 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Ifosfamide; Methotrexate; Mice; Mice, Nude; Paclitaxel; Survival Rate; Taxoids | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cyclophosphamide; Docetaxel; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, p53; Genes, Tumor Suppressor; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Paclitaxel; Preoperative Care; Receptors, Steroid; Taxoids; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2003 |
[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Stomach Neoplasms; Taxoids | 2003 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorometry; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Quality Control; Retrospective Studies; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2005 |
[Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Cerebrospinal Fluid; Cytarabine; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Spinal; Meningeal Neoplasms; Meningitis; Methotrexate; Quality of Life; Taxoids | 2005 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Areca; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Herb-Drug Interactions; Humans; Mastication; Methotrexate; Middle Aged; Mucositis; Taxoids | 2006 |
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Follicular; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Immunoenzyme Techniques; Mediastinal Neoplasms; Methotrexate; Middle Aged; Sarcoma; Taxoids; Treatment Outcome | 2006 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Heart Diseases; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Pilot Projects; Prospective Studies; Radiotherapy Dosage; Taxoids; Treatment Outcome | 2009 |
Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Taxoids | 2008 |
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Methotrexate; Mitoxantrone; Multidrug Resistance-Associated Proteins; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2009 |
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Topics: Adult; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Genes, BRCA1; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Registries; Taxoids | 2010 |
Neoadjuvant treatment in young women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2010 |
Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Therapy, Computer-Assisted; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2010 |
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Health Care Costs; Humans; Methotrexate; Middle Aged; Prognosis; Quality-Adjusted Life Years; Taxoids | 2011 |
Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
Topics: Adenocarcinoma; Administration, Metronomic; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Methotrexate; Prostatic Neoplasms; Salvage Therapy; Taxoids; Treatment Failure | 2011 |
Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Male; Methotrexate; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2012 |
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome; Young Adult | 2012 |
Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Menstrual Cycle; Methotrexate; Middle Aged; Multivariate Analysis; Premenopause; Prognosis; Proportional Hazards Models; Retrospective Studies; Taxoids; Young Adult | 2012 |
Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxanthine Phosphoribosyltransferase; Kallikreins; Methotrexate; RNA, Messenger; Taxoids | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Etoposide; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Methotrexate; Organoplatinum Compounds; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Repair; Docetaxel; Female; Fluorouracil; Homologous Recombination; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Taxoids; Triple Negative Breast Neoplasms | 2013 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Methotrexate; Multidrug Resistance-Associated Protein 2; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Taxoids; Tubulin | 2014 |
Participation of autophagy in the cytotoxicity against breast cancer cells by cisplatin.
Topics: Adenine; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Taxoids | 2015 |
Microencapsulated Multicellular Tumor Spheroids as a Tool to Test Novel Anticancer Nanosized Drug Delivery Systems In Vitro.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cells, Immobilized; Docetaxel; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Methotrexate; Nanoparticles; Spheroids, Cellular; Taxoids | 2015 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
PD-1 antibodies in head-and-neck cancer.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Programmed Cell Death 1 Receptor | 2019 |
Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Etoposide; Fluorouracil; HEK293 Cells; Humans; Lung Neoplasms; Membrane Proteins; Methotrexate; Mice; Molecular Targeted Therapy; Pemetrexed; Serine Endopeptidases | 2019 |
[Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)].
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
Topics: Antibodies, Monoclonal, Humanized; Cetuximab; Docetaxel; Humans; Methotrexate; Squamous Cell Carcinoma of Head and Neck | 2019 |
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Estrogen; Retrospective Studies; Survival Rate | 2020 |
Novel decorated nanostructured lipid carrier for simultaneous active targeting of three anti-cancer agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Carriers; Drug Liberation; Female; Humans; Lipids; Methotrexate; Nanostructures; Tumor Cells, Cultured | 2021 |
A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Retrospective Studies; Taxoids | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |